Mounjaro – which competes in the market with Novo Nordisk's GLP-1 agonist Ozempic (semaglutide) – was 8% better than ...

In May, the Danish pharma said CEO Lars Fruergaard Jørgensen would step down, following a turn in the obesity market. While Novo was the star of the emerging weight loss and diabetes market through ...

A Lilly study showed Mounjaro resulted in a lower risk of heart attacks and strokes in patients with diabetes compared with ...

A variety of GLP-1 drugs that were developed to treat Type 2 diabetes, including Novo Nordisk’s Ozempic, have secured label ...